论文部分内容阅读
本实验研究131I- angiostatin在荷Lewis肺癌C-57小鼠体内的分布,并进行放射受体显像,为临床应用提供依据。Angiostatin用氯胺-T法行131标记后,尾静脉注入荷肺癌C-57小鼠体内,24、48、96、144h后进行放射受体显像,并于48、96、144h分批处死实验小鼠,测定心脏等11种脏器和肿瘤组织的单位重量放射性比值（T/NT）、各组织摄取百分数（％ID/g）。结果发现,131I-angiostatin尾静脉注射后,48h内以全身分布为主,96h后肿瘤部位显像,并呈高度特异性浓集。γ显像结果与体内分布结果一致,SPECT图像质量与T/NT值有关。本研究证实131I-angiostatin可以特异地与肺癌组织内血管内皮细胞上的受体结合,具有导向肺癌组织的作用。
In this study, we investigated the distribution of 131I-angiostatin in Lewis lung carcinoma C-57 mice and performed radioactive receptor imaging to provide the basis for clinical application. Angiostatin was labeled with chloramine-T method 131 and then injected into tail vein to induce lung cancer C-57 mice. Radiographic receptor imaging was performed 24, 48, 96 and 144 hours later, and the rats were sacrificed at 48, 96 and 144 hours Mice were used to determine the ratio of radioactivity per unit weight (T / NT) and tissue uptake (% ID / g) in 11 kinds of organs such as heart. The results showed that, 131I-angiostatin tail vein injection, the main distribution within 48h, 96h after tumor imaging, and was highly specific concentration. γ imaging results and in vivo distribution of the same, SPECT image quality and T / NT value. This study confirmed that 131I-angiostatin can specifically bind to the receptors on vascular endothelial cells in lung cancer tissues and has the function of targeting lung cancer tissues.